Business

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the first quarter ended March 31, 2026, after the financial markets close on Wednesday, May 6, 2026. Wednesday, May 6th@ 4:

articleMineralys Therapeutics, Inc.April 29, 20261/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-wednesday-may-6-2026
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

About this update from Mineralys Therapeutics, Inc.

[{"type":"image","alt":"Mineralys Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Mineralys Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oMsxZW8ttKTHAHjG2pEt6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c","width":300,"height":79}},"lazy":false},{"type":"text","content":"RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the first quarter ended March 31, 2026, after the financial markets close on Wednesday, May 6, 2026.","length":477,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:45%;width:45%;min-width:45%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Wednesday, May 6th@ 4:30 p.m. ET","length":32,"tagName":"p","attribs":{}}]},{"style":"max-width:55%;width:55%;min-width:55%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Domestic:","length":9,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"1-877-704-4453","length":14,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"International:","length":14,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"1-201-389-0920","length":14,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Conference ID:","length":14,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middl...

More updates from Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.biopharmaceutical companyMineralys Therapeuticschronic kidney diseaseobstructive sleep apneaMineralys